2023
-
Thomas Smeenk provides an update on Hemostemix’s ACP-01 stem cell treatment for heart disease
Peter Clausi interviews Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an…
-
Contract to supply the U.S. Uranium Reserve puts Energy Fuels in the pilot’s seat for 2023
The uranium market had a reasonable 2022 with uranium prices up by 12%. The question on everyone’s mind…
-
Investing themes for 2023 Part 1 – Food Waste
Hello 2023! So long and good riddance to 2022. From a personal investment perspective, I’m more than happy…
